Cowen & Co. analyst Max Masucci initiates coverage on Evotec (NASDAQ:EVO) with a Outperform rating.
CTI BioPharma’s COVID-19 Candidate Misses Primary Endpoint Mark In Phase 2 Trial
CTI BioPharma Corp (NASDAQ:CTIC) has announced topline results from the PRE-VENT trial of pacritinib in hospitalized COVID-19 patients. The final PRE-VENT…